PAX3-FOXO1 drives targetable cell state-dependent metabolic vulnerabilities in rhabdomyosarcoma.

PAX3-FOXO1, an oncogenic transcription factor, drives a particularly aggressive subtype of rhabdomyosarcoma (RMS) by enforcing gene expression programs that support malignant cell states. Here we show that PAX3-FOXO1 RMS cells exhibit altered pyrimidine metabolism and increased dependence on enzymes involved in pyrimidine synthesis, including dihydrofolate reductase (DHFR). Consequently, PAX3-FOXO1 cells display increased sensitivity to inhibition of DHFR by the chemotherapeutic drug methotrexate, and this dependence is rescued by provision of pyrimidine nucleotides.

Novel inhibitors of the (VIBVN) NAT protein identified through pharmacophore modeling.

Arylamine N-acetyltransferases (NATs, E.C. 2.

Functional Connectivity Alterations Associated with COVID-19-Related Sleep Problems: A Longitudinal Resting-State fMRI Study.

Background: COVID-19 has led to reports of fatigue and sleep problems. Brain function changes underlying sleep problems (SP) post-COVID-19 are unclear.

Purpose: This study investigated SP-related brain functional connectivity (FC) alterations.

Metastasis lesion segmentation from bone scintigrams using encoder-decoder architecture model with multi-attention and multi-scale learning.

Background: The limitation in spatial resolution of bone scintigraphy, combined with the vast variations in size, location, and intensity of bone metastasis (BM) lesions, poses challenges for accurate diagnosis by human experts. Deep learning-based analysis has emerged as a preferred approach for automating the identification and delineation of BM lesions. This study aims to develop a deep learning-based approach to automatically segment bone scintigrams for improving diagnostic accuracy.

Roles of SPOCK1 in the Formation Mechanisms and Treatment of Non-Small-Cell Lung Cancer and Brain Metastases from Lung Cancer.

Lung cancer is a malignant tumor with high morbidity and mortality in China and worldwide. Once it metastasizes to the brain, its prognosis is very poor. Brain metastases are found in about 20% of newly diagnosed non-small-cell lung cancer (NSCLC) patients.